I Squared Announces Guillaume Pepy as Senior Policy Advisor
I Squared Capital, a leading independent global infrastructure investment manager, announced today that Guillaume Pepy, former CEO of French national rail group SNCF, is joining the firm as a Senior Policy Advisor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010873781/en/
Guillaume Pepy (Photo: Business Wire)
With an extensive background in the transportation industry, Guillaume will provide invaluable support to I Squared investment teams and portfolio companies within the mobility sector. I Squared currently has 18 portfolio companies within the transportation and logistics sector ranging from passenger services to trailer leasing operations. Guillaume also has a strong background in the public sector and will advise I Squared on ways to manage the different regulatory regimes and associated complexities in continental Europe.
“Guillaume has extensive experience within the transportation sector as well as a broad understanding of the policy and regulatory framework guiding the industry. We’re excited to have Guillaume join I Squared to work alongside our teams globally as they continue to identify opportunities within the transport and logistics sector,” said Mohamed El Gazzar, Senior Partner at I Squared. “With a distinguished and decades long career at SNCF, Guillaume is uniquely positioned to provide strategic insights and support to our portfolio companies as they continue to embrace emerging technologies and adapt to an ever-evolving regulatory landscape.”
“I’m thrilled to join the team at I Squared and help the company fulfill its mission of building more sustainable transportation infrastructure, an initiative that I care deeply about and to which I have dedicated much of my career,” Guillaume said. “We’re at an important point in history for the transportation sector where we are undergoing a trend of decarbonization and the need to upgrade aging infrastructure. I’m excited about the innovation happening at I Squared and I look forward to becoming a part of a team that is building the transportation of the future.”
Guillaume is a distinguished French business leader, most recognized for his long tenure at SNCF where he served as CEO from 2008 to 2019. While CEO, Guillaume led significant transformation at SNCF, expanding the railways’ global reach and modernizing its services to better compete in the rapidly evolving transportation industry. He was pivotal in promoting technological innovation and implementing strategic partnerships that positioned SNCF as a key player in global mobility.
In addition to his management role at SNCF, Guillaume has served in other influential positions including Chairman of Eurostar and Deputy Chairman of Keolis Group. Guillaume has also served in various high-ranking civil service positions in the French government including Deputy General Secretary of Conseil D’Etat, France’s highest administrative jurisdiction and Chief of Staff to Ministers of Civil Service and Labour. He has degrees from two French institutions, Sciences Po and Ecole Nationale d’Administration.
Guillaume is joining a network of approximately one dozen Senior Policy Advisors at I Squared that has expertise across a variety of industries including federal policy, water infrastructure and transportation, to name a few. A full list of I Squared’s Senior Policy Advisors is available on our website.
About I Squared
I Squared is a leading independent global infrastructure investor with over $40 billion in assets under management. We are known for the development of investment platforms in infrastructure projects where we start small and grow big. We use global insights and deep local intelligence to solve complex problems, foster smarter businesses, serve local communities, and invest in a more sustainable future to provide essential services to millions of people around the world. We are a team of over 280 people, headquartered in Miami with offices in Abu Dhabi, London, Munich, New Delhi, São Paulo, Singapore, Sydney and Taipei. We operate a diverse portfolio of 86 companies in more than 70 countries with over 66,000 employees in a variety of sectors including utilities, energy, digital infrastructure, transport, environmental infrastructure, and social infrastructure. You can find out more by visiting: www.isquaredcapital.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010873781/en/
Contacts
Media Contacts
Dominic McMullan / Shelly Hagan
info@isquaredcapital.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom